PFIZER INC (PFE)
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
📈 **POSITIVE** • Medium confidence analysis (76%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business